vorinostat and Recrudescence
vorinostat has been researched along with Recrudescence in 28 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"This study was undertaken to evaluate safety and pharmacokinetics and to determine treatment doses of vorinostat plus bortezomib in Japanese patients with relapsed or refractory multiple myeloma (MM)." | 9.22 | A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. ( Ando, K; Hanson, ME; Hotta, T; Koh, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimamoto, T; Suzuki, T; Tanaka, Y; Tobinai, K; Uchida, T; Watanabe, T, 2016) |
"The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents." | 9.22 | VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. ( Anderson, KC; Dimopoulos, M; Durrant, S; Eid, JE; Gause, C; Goldschmidt, H; Graef, T; Houp, J; Jagannath, S; Kaufman, JL; Leleu, X; Nagler, A; Offner, F; Siegel, DS; Vuocolo, S, 2016) |
"Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles." | 9.20 | A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015) |
"This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2." | 9.17 | A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013) |
"To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)." | 9.16 | Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. ( Bekele, NB; Borthakur, G; Brandt, M; Cortes, JE; de Lima, M; Faderl, S; Garcia-Manero, G; Hu, Y; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, MY; McCue, D; Newsome, WM; Pierce, SR; Ravandi, F; Tambaro, FP; Yang, H, 2012) |
" on days 1, 4, 8, and 11 and vorinostat at 100 to 500 mg orally daily for 8 days of each 21-day cycle in relapsed/refractory multiple myeloma patients." | 9.14 | Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. ( Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J, 2009) |
"This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone." | 7.83 | Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. ( Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH, 2016) |
"Increasing numbers of patients are presenting with relapsed/refractory multiple myeloma (MM) following treatment with bortezomib." | 7.76 | Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. ( Jagannath, S; Mazumder, A; Vesole, DH, 2010) |
"The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established." | 6.80 | Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015) |
"The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning, related donor hematopoietic cell transplantation (HCT)." | 5.24 | Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. ( Braun, T; Choi, SW; Dinarello, CA; Gatza, E; Henig, I; Magenau, J; Parkin, B; Pawarode, A; Reddy, P; Riwes, M; Yanik, G, 2017) |
"This study was undertaken to evaluate safety and pharmacokinetics and to determine treatment doses of vorinostat plus bortezomib in Japanese patients with relapsed or refractory multiple myeloma (MM)." | 5.22 | A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. ( Ando, K; Hanson, ME; Hotta, T; Koh, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimamoto, T; Suzuki, T; Tanaka, Y; Tobinai, K; Uchida, T; Watanabe, T, 2016) |
"The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents." | 5.22 | VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. ( Anderson, KC; Dimopoulos, M; Durrant, S; Eid, JE; Gause, C; Goldschmidt, H; Graef, T; Houp, J; Jagannath, S; Kaufman, JL; Leleu, X; Nagler, A; Offner, F; Siegel, DS; Vuocolo, S, 2016) |
"Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles." | 5.20 | A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. ( Andritsos, LA; Baiocchi, RA; Benson, DM; Bingman, A; Blum, K; Bowers, MA; Devine, SM; Earl, CT; Flynn, J; Geyer, S; Hade, EM; Hofmeister, CC; Humphries, K; Jaglowski, SM; Lozanski, G; Penza, S; Porcu, P; Vaughn, J; Williams, N, 2015) |
"This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2." | 5.17 | A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013) |
"To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)." | 5.16 | Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. ( Bekele, NB; Borthakur, G; Brandt, M; Cortes, JE; de Lima, M; Faderl, S; Garcia-Manero, G; Hu, Y; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, MY; McCue, D; Newsome, WM; Pierce, SR; Ravandi, F; Tambaro, FP; Yang, H, 2012) |
" on days 1, 4, 8, and 11 and vorinostat at 100 to 500 mg orally daily for 8 days of each 21-day cycle in relapsed/refractory multiple myeloma patients." | 5.14 | Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. ( Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J, 2009) |
"This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone." | 3.83 | Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. ( Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH, 2016) |
"Increasing numbers of patients are presenting with relapsed/refractory multiple myeloma (MM) following treatment with bortezomib." | 3.76 | Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. ( Jagannath, S; Mazumder, A; Vesole, DH, 2010) |
" We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL." | 2.82 | Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. ( Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH, 2016) |
"The standard treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in frail elderly patients has not been established." | 2.80 | Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation. ( Cella, D; Drullinsky, PR; Elstrom, R; Gerecitano, JF; Hamilton, AM; Hamlin, PA; Lia Palomba, M; Matasar, MJ; Noy, A; Straus, DJ; Wegner, B; Wortman, K; Zelenetz, AD, 2015) |
"Oral vorinostat 200 mg was administered twice daily on days 1-14 along with 375 mg/m(2) of intravenous rituximab on day 1 of a 21-day cycle, continuing until disease progression or unacceptable toxicity." | 2.80 | A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. ( Chen, R; Forman, SJ; Frankel, P; Htut, M; Kirschbaum, M; Mott, M; Nademanee, A; Nathwani, N; Popplewell, L; Rotter, A; Ruel, N; Siddiqi, T; Thomas, SH, 2015) |
"Vorinostat was given at 200 mg/day to 1000 mg/day (days -8 to -3)." | 2.80 | Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015) |
" In conclusion, the poor results obtained with lenalidomide in combination with vorinostat and dexamethasone provide no arguments that could justify further investigation of this drug combination for the treatment of relapsed PTCL." | 2.79 | Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. ( Egle, A; Greil, R; Hopfinger, G; Lang, A; Linkesch, W; Melchardt, T; Nösslinger, T; Weiss, L, 2014) |
"To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts." | 2.78 | Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. ( Anyang, BN; Baer, MR; Beumer, JH; Carrier, F; Espinoza-Delgado, I; Fang, HB; Gojo, I; Lapidus, R; Ross, DD; Sadowska, M; Srivastava, RK; Tan, M, 2013) |
" There was no clear relationship between vorinostat dosage and drug exposure over the dose range studied." | 2.78 | A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. ( Ahern, C; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Horton, T; Hummel, TR; Ingle, AM; McGovern, RM; Reid, JM; Wagner, L; Weigel, B, 2013) |
" HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro." | 2.75 | A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. ( Egorin, MJ; Espinoza-Delgado, I; Ferrajoli, A; Garcia-Manero, G; Holleran, JL; Kadia, TM; Kantarjian, HM; Madden, TL; Maddipotti, S; Newsome, W; Ravandi, F; Sanchez-Gonzalez, B; Schroeder, C; Thomas, DA; Yang, H; Zwiebel, JA, 2010) |
"Vorinostat was well tolerated at 300 mg b." | 2.73 | Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. ( Cheson, BD; Coiffier, B; Crump, M; Frankel, SR; Jacobsen, ED; Randolph, SS; Ricker, JL; Sun, L; Xie, H, 2008) |
"Vorinostat (Zolinza) is a histone deacetylase inhibitor that has demonstrated activity in patients with advanced solid tumors in phase I trials." | 2.73 | Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. ( Chen, C; Dumez, H; Randolph, SS; Ricker, JL; Schöffski, P; Van Cutsem, E; Vansteenkiste, J, 2008) |
"A number of new agents in acute myeloid leukemia (AML) have held much promise in recent years, but most have failed to change the therapeutic landscape." | 2.49 | New agents: great expectations not realized. ( Lancet, JE, 2013) |
Research
Studies (28)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (10.71) | 29.6817 |
2010's | 22 (78.57) | 24.3611 |
2020's | 3 (10.71) | 2.80 |
Authors
Authors | Studies |
---|---|
Alatrash, G | 1 |
Saberian, C | 1 |
Bassett, R | 1 |
Thall, PF | 2 |
Ledesma, C | 1 |
Lu, Y | 1 |
Daher, M | 1 |
Valdez, BC | 2 |
Kawedia, J | 1 |
Popat, U | 2 |
Mehta, R | 1 |
Oran, B | 1 |
Nieto, Y | 2 |
Olson, A | 1 |
Anderlini, P | 2 |
Marin, D | 1 |
Hosing, C | 2 |
Alousi, AM | 1 |
Shpall, EJ | 3 |
Rondon, G | 1 |
Chen, J | 1 |
Qazilbash, M | 2 |
Champlin, RE | 1 |
Kebriaei, P | 1 |
Janku, F | 1 |
Park, H | 1 |
Call, SG | 1 |
Madwani, K | 1 |
Oki, Y | 2 |
Subbiah, V | 1 |
Hong, DS | 1 |
Naing, A | 1 |
Velez-Bravo, VM | 1 |
Barnes, TG | 1 |
Hagemeister, FB | 1 |
Falchook, GS | 1 |
Karp, DD | 1 |
Wheler, JJ | 1 |
Piha-Paul, SA | 1 |
Garrido-Laguna, I | 1 |
Fayad, LE | 1 |
Neelapu, SS | 1 |
Meric-Bernstam, F | 1 |
Kurzrock, R | 1 |
Fanale, MA | 1 |
Brown, S | 1 |
Pawlyn, C | 1 |
Tillotson, AL | 1 |
Sherratt, D | 1 |
Flanagan, L | 1 |
Low, E | 1 |
Morgan, GJ | 1 |
Williams, C | 1 |
Kaiser, M | 1 |
Davies, FE | 1 |
Jenner, MW | 1 |
Choi, SW | 1 |
Braun, T | 2 |
Henig, I | 1 |
Gatza, E | 1 |
Magenau, J | 1 |
Parkin, B | 1 |
Pawarode, A | 1 |
Riwes, M | 1 |
Yanik, G | 1 |
Dinarello, CA | 1 |
Reddy, P | 1 |
Gojo, I | 1 |
Tan, M | 1 |
Fang, HB | 1 |
Sadowska, M | 1 |
Lapidus, R | 1 |
Baer, MR | 2 |
Carrier, F | 1 |
Beumer, JH | 1 |
Anyang, BN | 1 |
Srivastava, RK | 1 |
Espinoza-Delgado, I | 4 |
Ross, DD | 1 |
Holkova, B | 1 |
Supko, JG | 1 |
Ames, MM | 2 |
Reid, JM | 2 |
Shapiro, GI | 1 |
Perkins, EB | 1 |
Ramakrishnan, V | 1 |
Tombes, MB | 1 |
Honeycutt, C | 1 |
McGovern, RM | 2 |
Kmieciak, M | 1 |
Shrader, E | 1 |
Wellons, MD | 1 |
Sankala, H | 1 |
Doyle, A | 1 |
Wright, J | 1 |
Roberts, JD | 1 |
Grant, S | 2 |
Hummel, TR | 1 |
Wagner, L | 1 |
Ahern, C | 1 |
Fouladi, M | 1 |
Gilbertson, RJ | 1 |
Horton, T | 1 |
Ingle, AM | 1 |
Weigel, B | 1 |
Blaney, SM | 1 |
Prebet, T | 1 |
Beyne-Rauzy, O | 1 |
Dreyfus, F | 1 |
Stammatoullas, A | 1 |
Wattel, E | 1 |
Ame, S | 1 |
Raffoux, E | 1 |
Delaunay, J | 1 |
Charbonnier, A | 1 |
Adès, L | 1 |
Fenaux, P | 1 |
Vey, N | 1 |
Walter, RB | 1 |
Medeiros, BC | 1 |
Gardner, KM | 1 |
Orlowski, KF | 1 |
Gallegos, L | 1 |
Scott, BL | 1 |
Hendrie, PC | 1 |
Estey, EH | 1 |
Lancet, JE | 1 |
Hopfinger, G | 1 |
Nösslinger, T | 1 |
Lang, A | 1 |
Linkesch, W | 1 |
Melchardt, T | 1 |
Weiss, L | 1 |
Egle, A | 1 |
Greil, R | 1 |
Ogura, M | 2 |
Ando, K | 2 |
Suzuki, T | 2 |
Ishizawa, K | 1 |
Oh, SY | 1 |
Itoh, K | 1 |
Yamamoto, K | 2 |
Au, WY | 1 |
Tien, HF | 1 |
Matsuno, Y | 1 |
Terauchi, T | 1 |
Mori, M | 1 |
Tanaka, Y | 2 |
Shimamoto, T | 2 |
Tobinai, K | 2 |
Kim, WS | 2 |
Hofmeister, CC | 1 |
Williams, N | 1 |
Geyer, S | 1 |
Hade, EM | 1 |
Bowers, MA | 1 |
Earl, CT | 1 |
Vaughn, J | 1 |
Bingman, A | 1 |
Humphries, K | 1 |
Lozanski, G | 1 |
Baiocchi, RA | 1 |
Jaglowski, SM | 1 |
Blum, K | 1 |
Porcu, P | 1 |
Flynn, J | 1 |
Penza, S | 1 |
Benson, DM | 1 |
Andritsos, LA | 1 |
Devine, SM | 1 |
Straus, DJ | 1 |
Hamlin, PA | 1 |
Matasar, MJ | 1 |
Lia Palomba, M | 1 |
Drullinsky, PR | 1 |
Zelenetz, AD | 1 |
Gerecitano, JF | 1 |
Noy, A | 1 |
Hamilton, AM | 1 |
Elstrom, R | 1 |
Wegner, B | 1 |
Wortman, K | 1 |
Cella, D | 1 |
Chen, R | 1 |
Frankel, P | 1 |
Popplewell, L | 1 |
Siddiqi, T | 1 |
Ruel, N | 1 |
Rotter, A | 1 |
Thomas, SH | 1 |
Mott, M | 1 |
Nathwani, N | 1 |
Htut, M | 1 |
Nademanee, A | 1 |
Forman, SJ | 1 |
Kirschbaum, M | 1 |
How, J | 1 |
Minden, MD | 1 |
Brian, L | 1 |
Chen, EX | 1 |
Brandwein, J | 1 |
Schuh, AC | 1 |
Schimmer, AD | 1 |
Gupta, V | 1 |
Webster, S | 1 |
Degelder, T | 1 |
Haines, P | 1 |
Stayner, LA | 1 |
McGill, S | 1 |
Wang, L | 1 |
Piekarz, R | 1 |
Wong, T | 1 |
Siu, LL | 1 |
Holleran, JL | 3 |
Egorin, MJ | 3 |
Yee, KW | 1 |
Ahmed, S | 1 |
Jones, RB | 1 |
Gulbis, A | 1 |
Alousi, A | 1 |
Shah, N | 1 |
Bashir, Q | 1 |
Liu, Y | 1 |
Hagemeister, F | 1 |
Fanale, M | 1 |
Dabaja, B | 1 |
Pinnix, C | 1 |
Champlin, R | 1 |
Andersson, BS | 1 |
Ogawa, Y | 1 |
Watanabe, T | 1 |
Ohmachi, K | 1 |
Uchida, T | 1 |
Hanson, ME | 1 |
Koh, Y | 1 |
Hotta, T | 1 |
Shin, DY | 1 |
Kim, SJ | 1 |
Yoon, DH | 1 |
Park, Y | 1 |
Kong, JH | 1 |
Kim, JA | 1 |
Kim, BS | 1 |
Kim, HJ | 1 |
Won, JH | 1 |
Park, SK | 1 |
Siegel, DS | 2 |
Dimopoulos, M | 1 |
Jagannath, S | 2 |
Goldschmidt, H | 1 |
Durrant, S | 1 |
Kaufman, JL | 1 |
Leleu, X | 1 |
Nagler, A | 1 |
Offner, F | 1 |
Graef, T | 2 |
Eid, JE | 1 |
Houp, J | 1 |
Gause, C | 1 |
Vuocolo, S | 1 |
Anderson, KC | 2 |
Bilotti, E | 1 |
Vesole, DH | 2 |
McBride, L | 1 |
Schmidt, L | 1 |
Gao, Z | 1 |
Gilani, M | 1 |
McNeill, A | 1 |
Bednarz, U | 1 |
Richter, J | 1 |
Mato, A | 1 |
Badros, A | 1 |
Burger, AM | 1 |
Philip, S | 1 |
Niesvizky, R | 1 |
Kolla, SS | 1 |
Goloubeva, O | 1 |
Harris, C | 1 |
Zwiebel, J | 1 |
Wright, JJ | 1 |
Mazumder, A | 1 |
Kadia, TM | 2 |
Yang, H | 2 |
Ferrajoli, A | 1 |
Maddipotti, S | 1 |
Schroeder, C | 1 |
Madden, TL | 1 |
Ravandi, F | 2 |
Thomas, DA | 1 |
Newsome, W | 1 |
Sanchez-Gonzalez, B | 1 |
Zwiebel, JA | 1 |
Kantarjian, HM | 2 |
Garcia-Manero, G | 2 |
Tambaro, FP | 1 |
Bekele, NB | 1 |
Jabbour, E | 1 |
Borthakur, G | 1 |
Konopleva, MY | 1 |
Faderl, S | 1 |
Cortes, JE | 1 |
Brandt, M | 1 |
Hu, Y | 1 |
McCue, D | 1 |
Newsome, WM | 1 |
Pierce, SR | 1 |
de Lima, M | 1 |
Alsina, M | 1 |
Bensinger, W | 1 |
Biermann, JS | 1 |
Cohen, AD | 1 |
Devine, S | 1 |
Djulbegovic, B | 1 |
Faber, EA | 1 |
Gasparetto, C | 1 |
Hernandez-Illizaliturri, F | 1 |
Huff, CA | 1 |
Kassim, A | 1 |
Krishnan, AY | 1 |
Liedtke, M | 1 |
Meredith, R | 1 |
Raje, N | 1 |
Schriber, J | 1 |
Singhal, S | 1 |
Somlo, G | 1 |
Stockerl-Goldstein, K | 1 |
Treon, SP | 1 |
Weber, D | 1 |
Yahalom, J | 1 |
Yunus, F | 1 |
Shead, DA | 1 |
Kumar, R | 1 |
Crump, M | 1 |
Coiffier, B | 1 |
Jacobsen, ED | 1 |
Sun, L | 1 |
Ricker, JL | 2 |
Xie, H | 1 |
Frankel, SR | 1 |
Randolph, SS | 2 |
Cheson, BD | 1 |
Vansteenkiste, J | 1 |
Van Cutsem, E | 1 |
Dumez, H | 1 |
Chen, C | 1 |
Schöffski, P | 1 |
Clinical Trials (15)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer[NCT01087554] | Phase 1 | 249 participants (Anticipated) | Interventional | 2010-03-31 | Active, not recruiting | ||
A Phase II Trial of Combination Treatment With Vorinostat, Bortezomib and Dexamethasone in Patients With Relapsed and Relapsed Refractory Multiple Myeloma[NCT01720875] | Phase 2 | 16 participants (Actual) | Interventional | 2013-08-09 | Completed | ||
Pilot Trial of Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Allogeneic Transplant[NCT01790568] | Phase 2 | 26 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors[NCT01076530] | Phase 1 | 27 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
A Phase I/II Study of Vorinostat in Combination With Low Dose Ara-C for Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes[NCT00776503] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML)[NCT00895934] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL[NCT04423926] | Phase 1/Phase 2 | 91 participants (Anticipated) | Interventional | 2020-06-10 | Recruiting | ||
A Phase II Study of MK-0683 in Patients With Relapsed / Refractory Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL)[NCT00875056] | Phase 2 | 56 participants (Actual) | Interventional | 2009-04-15 | Completed | ||
Histone Deacetylase (HDAC) Inhibition Using Vorinostat (SAHA) After Autologous Hematopoietic Stem Cell Transplantation for High Risk Lymphoma[NCT00561418] | Phase 1 | 23 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
A Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma[NCT00720876] | Phase 2 | 30 participants (Actual) | Interventional | 2008-07-23 | Completed | ||
Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies[NCT01421173] | Phase 1 | 78 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
A Multicenter, Open-Label, Phase I Study of MK-0683 in Combination With Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma[NCT00858234] | Phase 1 | 9 participants (Actual) | Interventional | 2009-02-13 | Completed | ||
An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma[NCT00773838] | Phase 2 | 143 participants (Actual) | Interventional | 2008-12-01 | Completed | ||
A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00097929] | Phase 2 | 18 participants (Actual) | Interventional | 2005-05-01 | Completed | ||
A Phase II Clinical Study of Oral Suberoylanilide Hydroxamic Acid in Patients With Relapsed or Refractory Breast, Colorectal, and Non-small Cell Lung Cancer.[NCT00126451] | Phase 2 | 16 participants (Actual) | Interventional | 2004-12-01 | Terminated | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Non-Relapse Mortality Incidence
(NCT01790568)
Timeframe: 1 year
Intervention | percentage of patients (Number) |
---|---|
Vorinostat | 16 |
Percentage of Patients Alive at 1 Year
Overall survival at 1 Year. (NCT01790568)
Timeframe: 1 Year
Intervention | percentage of patients (Number) |
---|---|
Vorinostat | 76 |
Percentage of Patients That Experience Grade 2-4 GVHD Within 100 Days of Transplant
"GVHD Staging:~Grade 2: (Skin) Maculopapular rash 25-50% BSA, (Liver) bilirubin 3.1-6mg/dl, (Gut) 1000-1500 ml/day for adult and 20-30ml/kg/day for child.~Grade 3: (Skin) Maculopapular rash >50% BSA, (Liver) 6.1-15mg/dl, (Gut) >1500mg/day for adult and >30ml/kg/day for child.~Grade 4: (Skin) Generalized erythroderma plus bullous formation and desquamation >5% BSA, (Liver) >15mg/dl, (Gut) Severe abdominal pain with or without ileus, or grossly bloody stool." (NCT01790568)
Timeframe: 100 Days
Intervention | percentage of patients (Number) |
---|---|
Vorinostat | 22 |
Disease Relapse
(NCT00895934)
Timeframe: up to 2 years
Intervention | Participants (Count of Participants) |
---|---|
Phase 2/Selected Dose | 5 |
Number of Participants With Complete Remission
Efficacy Defined as Best Response Achieved During Study Treatment Measured by Complete Remission (CR) Rate (NCT00895934)
Timeframe: up to 3 years
Intervention | Participants (Count of Participants) |
---|---|
Phase 2/Selected Dose | 18 |
Number of Participants With Dose-limiting Toxicity (Phase I)
(NCT00895934)
Timeframe: 42 days
Intervention | participants (Number) |
---|---|
Dose 1 | 0 |
Dose 2 | 0 |
Dose 3 | 0 |
Dose 4 | 1 |
Number of Participants With Dose-limiting Toxicity After the Vorinostat Dose
(NCT00895934)
Timeframe: Up to 3 years
Intervention | participants (Number) |
---|---|
Phase 1 Dose-Finding Cohorts 1-3 | 4 |
Phase 2/Selected Dose | 18 |
Number of Participants Who Discontinued Study Drug Due to Experiencing an Adverse Event (AE)
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued from study drug due to an adverse event was reported. (NCT00875056)
Timeframe: Up to 536 days
Intervention | Participants (Count of Participants) |
---|---|
Follicular Lymphoma (FL) | 6 |
Indolent Non-FL B-NHL or MCL | 1 |
Other Disease | 2 |
Number of Participants Who Experienced an Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have a causal relationship with this treatment. The number of participants who experienced an AE was presented. (NCT00875056)
Timeframe: Up to approximately 29 months
Intervention | Participants (Count of Participants) |
---|---|
Follicular Lymphoma (FL) | 39 |
Indolent Non-FL B-NHL or MCL | 11 |
Other Disease | 6 |
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who had a Complete Response (CR: Normal liver/spleen physical exam, all lymph nodes and nodal masses are normal, and there is no bone marrow involvement), a Complete Response/unconfirmed (CRu: Normal liver/spleen physical exam, plus at least a 75% decrease in the sum of the products of the greatest diameters of nodal masses if any are greater than 1.5 cm in their greatest diameter, normal or indeterminate bone marrow involvement), or a Partial Response (PR: Either normal physical exam, lymph nodes, and lymph node masses plus positive bone marrow involvement; OR normal physical exam or decrease in liver/spleen size plus at least a 50% decrease in the diameters of lymph nodes and nodal masses) as assessed using the international working group Non-Hodgkin's lymphoma standardized response criteria described by Cheson, BD in 1999. The percentage of participants who experienced a CR, CRu, or PR is presented. (NCT00875056)
Timeframe: Up to 650 days
Intervention | Percentage of participants (Number) |
---|---|
Follicular Lymphoma (FL) | 48.7 |
Indolent Non-FL B-NHL or MCL | 27.3 |
Time to Response for Relapsed/Refractory FL
Time to Response is defined as the time from allocation until the time of an initial response. Data was censored on the efficacy data cutoff date of 25 February, 2011. (NCT00875056)
Timeframe: Up to 650 days
Intervention | Days (Median) |
---|---|
Follicular Lymphoma (FL) | NA |
Time to Treatment Failure for Relapsed/Refractory FL
Time to Treatment Failure is defined as the time from allocation until the date of any treatment failure, including documented disease progression, or discontinuation of the study medication for any reason. Data was censored on the efficacy data cutoff date of 25 February, 2011. (NCT00875056)
Timeframe: Up to 650 days
Intervention | Days (Median) |
---|---|
Follicular Lymphoma (FL) | 323 |
Duration of Response
Median follow up of living patients (NCT00561418)
Timeframe: Up to 5 years
Intervention | months (Median) |
---|---|
Vorinostat (SAHA) | 23.2 |
Clinical Benefit
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00561418)
Timeframe: Up to 3 years
Intervention | patients (Number) | |||
---|---|---|---|---|
Complete Response (CR) | Partial Response (PR) | Stable Disease(SD) | Not evaluable | |
Vorinostat (SAHA) | 13 | 3 | 2 | 5 |
Safety and Tolerability of Vorinostat (SAHA) After Autologous Stem Cell Transplantation
NCI CTCAE version 3.0 was used to assess Adverse Events (AE) Grade 1=Mild AE Grade 2=Moderate AE Grade 3=Severe AE Grade 4=Life-threatening or disabling AE (NCT00561418)
Timeframe: Up to 3 years
Intervention | patients (Number) | ||||
---|---|---|---|---|---|
Fatigue (Grade 1, 2) | Lymphopenia (Grade 1-4) | Thrombocytopenia (Grade 1-3) | Leukopenia (Grade 1-3) | Anemia (Grade 1-3) | |
Vorinostat (SAHA) | 12 | 11 | 11 | 10 | 10 |
Overall Response Rate (Complete and Partial Response)
Response was assessed according to the 2007 Cheson criteria using CT scans or PET: Complete Response (CR), Disappearance of all evidence of disease; Partial Response (PR), >=50% decrease in the Sum of the Product of Diameters (SPD) of up to 6 largest dominant masses and no increase in the size of other nodes; Overall Response (OR) = CR + PR. (NCT00720876)
Timeframe: After every 3 cycles, up to 1 year after the start of treatment
Intervention | percentage of participants (Number) |
---|---|
Vorinostat and Rituximab | 46 |
Progression-free Survival
ProgressionRelapse is defined using the 2007 Cheson criteria, as appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy; or at least a 50% increase for nadir in the SPD of any previously involved nodes; or at least a 50% increase in the longest diameter of any singe previously identified node more than 1 cm in its short axis. Estimated using the product-limit method of Kaplan and Meier. (NCT00720876)
Timeframe: Until disease progress
elapse, up to 1 year after the start of treatment
Intervention | Months (Median) |
---|---|
Vorinostat and Rituximab | 29.2 |
Number of Participants With Grade 3 and 4 Toxicities
Grade 3 & 4 toxicities at least possible related to study drugs during any cycle of treatment. Toxicity graded according to Common Terminology Criteria for Adverse Events version 3.0. (NCT00720876)
Timeframe: 3 weeks after the stop of treatment
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neutrophil count decreased | Platelet count decreased | Hemoglobin decreased | Lymphocyte count decreased | Hypotension | Chills | Fatigue | Dehydration | Diarrhea | Kidney infection | Pneumonia | Sepsis | Urinary tract infection | Localized edema | Alanine aminotransferase increased | Aspartate aminotransferase increased | Blood glucose increased | Serum phosphate decreased | Serum potassium decreased | Muscle weakness | Syncope | Hypoxia | Pneumonitis | Thrombosis | Vascular access complication | |
Vorinostat and Rituximab | 3 | 5 | 1 | 7 | 2 | 1 | 9 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 4 | 1 |
Number of Participants With an Adverse Event (AE)
The number of participants with ≥1 AE is reported. An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product(s), whether or not considered related to the use of the product(s). (NCT00858234)
Timeframe: Up to 346 days (up to 30 days after the final dose of study treatment)
Intervention | Participants (Count of Participants) |
---|---|
Vorinostat + Bortezomib | 9 |
Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1
The number of participants with ≥1 DLT during Cycle 1 is reported. A DLT is defined as an event considered by the investigator to be related to study treatment, and either: 1) a Grade 3 or 4 non-hematologic event (except for manageable toxicity by supportive care or non-prohibited therapies, or a transient increase in alanine aminotransferase [ALT]/aspartate aminotransferase [AST]); or 2) a Grade 4 hematologic toxicity except neutropenia or hemoglobin decreased (neutropenia was a DLT if it was Grade 3-4 with fever ≥38.5°C; Grade 3-4 with an infection requiring antibiotic/antifungal therapy; or Grade 4 and lasting ≥5 days). (NCT00858234)
Timeframe: Up to 21 days
Intervention | Participants (Count of Participants) |
---|---|
Vorinostat + Bortezomib | 1 |
Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Vorinostat Administered With Bortezomib on Days 1 and 11
The AUC0-24hr of vorinostat in plasma on Days 1 and 11 is reported in participants who also received bortezomib. (NCT00858234)
Timeframe: Predose and 0.8, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Days 1 and 11
Intervention | µM*hr (Least Squares Mean) | |
---|---|---|
Day 1 | Day 11 | |
Vorinostat + Bortezomib | 5.41 | 5.84 |
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinued study treatment due to an AE were reported. (NCT00773838)
Timeframe: Up to approximately 18 months
Intervention | Participants (Count of Participants) |
---|---|
Vorinostat + Bortezomib | 28 |
Number of Participants Who Experienced an Adverse Event (AE)
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experienced an AE were reported. (NCT00773838)
Timeframe: Up to approximately 22 months
Intervention | Participants (Count of Participants) |
---|---|
Vorinostat + Bortezomib | 142 |
Objective Response Rate (RR)
Objective RR was defined as percentage (%) of participants with complete response (CR: disappearance of original monoclonal (M) paraprotein from blood & urine on at least 2 determinations for at least 6 weeks (WKs) by immunofixation studies, <5% plasma cells in bone marrow on at least 1 determination, no increase in size/number of lytic bone lesions (LBLs) & disappearance of soft tissue plasmacytomas (STP) for at least 6 WKs on skeletal survey (SS) if available) or partial response (PR: ≥50% reduction in serum M protein for at least 2 determinations 6 WKs apart, if present, reduction in 24-hour urinary light chain excretion by ≥90% or ≤200 mg for at least 2 determinations 6 WKs apart, ≥50% reduction in STP size for at least 6 WKs, & no increase in size/number of LBLs on SS if available) as assessed by Independent Adjudication Committee (IAC) per European Blood & Marrow Transplant (EBMT) criteria. To report RR & 95% confidence intervals (CIs), exact test of binomial parameter was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)
Intervention | Percentage of Participants (Number) |
---|---|
Vorinostat + Bortezomib | 11.3 |
Overall Survival (OS)
OS was defined as the time from allocation to death due to any cause. To report the median survival (in months) and the associated 95%CIs were reported using Kaplan-Meier method was used. Participants without documented death at the time of final analysis were censored at the date of the last follow up. (NCT00773838)
Timeframe: Up to approximately 40 months (through End of Trial data cut-off of 09-Apr-2012)
Intervention | Months (Median) |
---|---|
Vorinostat + Bortezomib | 11.23 |
PFS as Assessed by Investigator Per EBMT Criteria
PFS was defined as the time from allocation to the first documents PD as assessed by investigator per EBMT criteria or death due to any cause, whichever occurs first. PD: >25% increase in level of serum M-paraprotein, which must also be an absolute increase of at least 5g/L (500 mg/dL) and confirmed on a repeat investigation or 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg/24hour and confirmed on a repeat investigation or >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10% or definitive increase in size of existing LBLs or STP or development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). To report the median PFS (in months) and associated 95%CIs Kaplan-Meier method was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)
Intervention | Months (Median) |
---|---|
Vorinostat + Bortezomib | 2.83 |
Progression-Free Survival (PFS) as Determined by IAC Per EBMT Criteria
PFS was defined as the time from allocation to the first documents PD as determined by IAC per EBMT criteria or death due to any cause, whichever occurs first. PD: >25% increase in level of serum M-paraprotein, which must also be an absolute increase of at least 5g/L (500 mg/dL) and confirmed on a repeat investigation or 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg/24hour and confirmed on a repeat investigation or >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10% or definitive increase in size of existing LBLs or STP or development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). To report the median PFS (in months) and associated 95%CIs Kaplan-Meier method was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)
Intervention | Months (Median) |
---|---|
Vorinostat + Bortezomib | 3.13 |
Time To Disease Progression (TTP) as Determined by IAC Per EBMT Criteria
TTP was defined as the time from allocation to the first documented disease progression (PD) as determined by IAC per EBMT criteria or death due to myeloma, whichever occurred first. PD: >25% increase in level of serum Mparaprotein, which must also be an absolute increase of at least 5g/L (500 mg/dL) and confirmed on a repeat investigation or 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg/24hour and confirmed on a repeat investigation or >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10% or definitive increase in size of existing LBLs or STP or development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). To report the median TTP (in months) and associated 95% CIs Kaplan-Meier method was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)
Intervention | Months (Median) |
---|---|
Vorinostat + Bortezomib | 3.47 |
TTP as Assessed by Investigator Per EBMT Criteria
TTP was defined as the time from allocation to the first documented PD as assessed by investigator per EBMT criteria or death due to myeloma, whichever occurred first. PD: >25% increase in level of serum Mparaprotein, which must also be an absolute increase of at least 5g/L (500 mg/dL) and confirmed on a repeat investigation or 25% increase in 24-hour urinary light chain excretion, which must also be an absolute increase of at least 200mg/24hour and confirmed on a repeat investigation or >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy, which must also be an absolute increase of at least 10% or definitive increase in size of existing LBLs or STP or development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause). To report the median TTP (in months) and associated 95% CIs Kaplan-Meier method was used. (NCT00773838)
Timeframe: Up to approximately 30 months (through Final Analysis data cut-off of 16-May-2011)
Intervention | Months (Median) |
---|---|
Vorinostat + Bortezomib | 3.07 |
Reviews
1 review available for vorinostat and Recrudescence
Article | Year |
---|---|
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzo | 2013 |
Trials
24 trials available for vorinostat and Recrudescence
Article | Year |
---|---|
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoieti | 2022 |
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brentuxi | 2020 |
Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Dexamethasone; | 2021 |
Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.
Topics: Acetylation; Acute Disease; Adolescent; Adult; Aged; Demography; Feasibility Studies; Female; Graft | 2017 |
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 2013 |
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemo | 2013 |
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2013 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Do | 2014 |
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Topics: Age Factors; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo | 2014 |
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy | 2014 |
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; CREB-Binding Protein; DNA Mutational | 2014 |
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
Topics: Administration, Oral; Adult; Aged; Child; Combined Modality Therapy; Diarrhea; Disease-Free Survival | 2015 |
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2015 |
A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2015 |
A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitab | 2015 |
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Dr | 2015 |
A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Hydroxamic Acid | 2016 |
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Resistance, Neoplasm; Female; Human | 2016 |
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Respons | 2009 |
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Topics: Acetylation; Acute Disease; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combi | 2010 |
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema | 2012 |
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug | 2008 |
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neop | 2008 |
Other Studies
3 other studies available for vorinostat and Recrudescence
Article | Year |
---|---|
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Hy | 2016 |
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease | 2010 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; B | 2013 |